Clinical trials: AD
Adenovirus
Ad Sensor-based Real-time Diagnosis of Adenovirus
To develop a real-time diagnostic technique with Ad sensor for Adenovirus detection, the investigators conduct a prospective clinical study.
- Trial name
- NCT02008812
- Testing
- Ad sensor
- Where
- Taiwan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Atopic Dermatitis
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 in the treatment of moderate-to-severe AD in adolescents.
- Trial name
- NCT06767540
- Where
- 28 sites in China
- Volunteers
- 198 people
- Sponsor
- Akeso
Alzheimer's Disease
Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)
Alzheimer Disease (AD) is a progressive brain disease generally known as senile dementia. Our proposed study will establish safety and pharmacokinetics of Meganatural-AZ GSPE in AD subjects.
- Trial name
- NCT02033941
- Testing
- Meganatural-Az Grapeseed Extract
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Hillel Grossman
Attention Deficit Disorder With Hyperactivity Disease, Hyperkinesis
Tipepidine in Children With Attention Deficit/Hyperactivity Disorder (AD/HD): a Double-blind, Placebo-controlled Trial
Tipepidine (3-[di-2-thienylmethylene]-1-methylpiperidine) has been used solely as a nonnarcotic antitussive in Japan since 1959. The safety of tipepidine in children and adults has already been established.
- Conditions
- Attention Deficit Disorder With Hyperactivity Disease, Hyperkinesis, Attention Deficit and Disruptive Behavior Disorders
- Trial name
- NCT02305134
- Testing
- Tipepidine Hibenzate
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Chiba University
Atopic Dermatitis
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, these studies included a limited…
- Trial name
- NCT05029895
- Where
- 61 sites in Japan
- Volunteers
- 167 people
- Sponsor
- AbbVie
Attention Deficit Disorder
Neurofeedback and Working Memory Training for Children and Adolescents With ADHD
The purpose of this study is to investigate if neurofeedback and working memory training improves core symptoms of ADHD in children and adolescents.
- Trial name
- KITE (NCT01841151)
- Testing
- SCP training, Live Z-score training, WM training
- Where
- Sweden
- Volunteers
- 202 people
- Sponsor
- Karolinska Institutet
Adolescent Participants With Moderate to Severe Atopic Dermatitis (AD)
Phase IIa Study of Pharmacokinetics, Safety and Efficacy of QY201 Tablets in Adolescent Subjects With Moderate to Severe Atopic Dermatitis
To evaluate the population pharmacokinetic characteristics of QY201 Tablets in adolescent participants with moderate to severe atopic dermatitis (AD).
- Trial name
- NCT07712536
- Testing
- QY201 Tablets（10mg）, QY201 Tablets（20mg）
- Where
- China
- Volunteers
- 24 people
- Sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Mild Cognitive Impairment
Multi-modality MRI Study on Differences in Conversion of aMCI Patients With APOEε4 to AD
This study is to find out the imaging marker and the changing laws of the marker during the course of the disease. The final purpose is to provide scientific evidence for new prevention, diagnosis and treatment of Alzheimer's…
- Trial name
- NCT02225964
- Where
- China
- Volunteers
- 200 people
- Sponsor
- XuanwuH 2
Atopic Dermatitis
A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
This 4-week study will evaluate the safety and efficacy of crisaborole ointment 2%; crisaborole vehicle; topical corticosteroid and topical calcineurin inhibitor, applied twice daily (BID) in subjects who are at least 2 years of…
- Trial name
- NCT03539601
- Testing
- Crisaborole ointment, 2%, Hydrocortisone butyrate cream, 0.1%, Pimecrolimus cream, 1%
- Where
- 32 sites in United States, Germany and 5 more
- Volunteers
- 237 people
- Sponsor
- Pfizer
Autosomal Dominant Polycystic Kidney Disease
High Water Intake in Polycystic Kidney Disease
DRINK is an open-label randomised controlled feasibility trial of high versus ad libitum water intake in ADPKD.
- Trial name
- DRINK (NCT02933268)
- Testing
- High water intake, Ad libitum water intake
- Where
- United Kingdom
- Volunteers
- 42 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Atopic Dermatitis
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)
This is a A multicenter, open label, phase II clinical study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics(PD), and preliminary efficacy of AK120 in adolescents with moderate-to-severe atopic dermatitis
- Trial name
- NCT06756126
- Testing
- AK120
- Where
- 6 sites in China
- Volunteers
- 24 people
- Sponsor
- Akeso
Alzheimer's Disease
Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease
The primary purpose of this study is to assess the safety and tolerability of TRx0237 when taken at the same time as acetylcholinesterase inhibitors (i.e., donepezil, galantamine, or rivastigmine) and / or memantine to treat…
- Trial name
- NCT01626391
- Testing
- TRx0237
- Where
- 12 sites in Germany, United Kingdom
- Volunteers
- 9 people
- Sponsor
- TauRx Therapeutics Ltd
Atopic Dermatitis
AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes
The goal of this Phase 4 clinical study is to learn how Ebglyss (lebrikizumab) works and how it is dosed in everyday dermatology care for adults and adolescents (age 12 and older) with moderate-to-severe atopic dermatitis…
- Trial name
- AD-TEMPO (NCT07856134)
- Testing
- Lebrikizumab-lbkz
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Forefront Dermatology S.C
Alzheimer Disease (AD)
Improved Treatment and Monitoring of Alzheimer's Disease
In the world's high-income countries, Alzheimer's disease and other dementia diseases are currently the second most common cause of death.
- Trial name
- NCT07135245
- Testing
- Semaglutide (Rybelsus®) combined with other interventions, Semaglutide (Rybelsus®)
- Volunteers
- 180 people
- Sponsor
- Rune Skovgaard Rasmussen
Cognitive Impairment
Detection of AD Biomarkers in Tear Fluid
Detection of AD biomarkers in tear fluid
- Trial name
- SmartTears (NCT04620902)
- Testing
- Tear sampling
- Where
- Netherlands
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center